Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enasidenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 known ✓ | P48735 | 13/20 | 1.00 |
| ▸ | IDH1 | O75874 | 13/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.91 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.91 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.91 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.91 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.91 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.91 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.91 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.91 |
| ▸ | KDR | P35968 | 1/20 | 0.91 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enasidenib SCHEMBL16448052 | 1.00 | IDH2 (1.00) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| Enasidenib SCHEMBL29360046 | 0.95 | IDH2 (1.00) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| Enasidenib SCHEMBL15102202 | 0.95 | IDH2 (1.00) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL15102425 | 0.92 | IDH1 (0.93) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL15102444 | 0.92 | IDH1 (0.93) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| Enasidenib SCHEMBL17891027 | 0.89 | IDH2 (0.87) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL18774517 | 0.88 | IDH2 (0.85) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL15102582 | 0.88 | IDH2 (0.85) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL29560993 | 0.88 | IDH2 (0.85) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL15102481 | 0.88 | IDH1 (0.85) | IDH2IDH1ABCB11ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335450-A1 | TABLET COMPOSITIONS | CELGENE CORP (US) | 2024-10-10 | — | — | US | disclosed |
| US-20220323447-A1 | TABLET COMPOSITIONS | CELGENE CORP (US) | 2022-10-13 | — | — | US | disclosed |
| US-11389454-B2 | Tablet compositions | CELGENE CORPORATION (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220323447-A1 | TABLET COMPOSITIONS | HTR3D, TPP2, TPMT | IDH2 3752/4885IDH1 2403/4885ABCB11 485/4885 |
| US-11389454-B2 | Tablet compositions | TPP2, HTR3D, SLC5A2 | IDH2 3643/4885IDH1 2222/4885ABCB11 433/4885 |
| US-20240335450-A1 | TABLET COMPOSITIONS | TPP2, HTR3D, SLC5A2 | IDH2 3643/4885IDH1 2222/4885ABCB11 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.